Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Mabwell (Shanghai) Bioscience Co: Clinical Trials & FDA Approval Profile

Mabwell (Shanghai) Bioscience Co (Global / Institutional) sponsors 36 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 18 active protocols (12 recruiting now), 4 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)2.8%
Median Closed Enrollment vs National (145 pts)517 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Mabwell (Shanghai) Bioscience Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)36
Active Pipeline (Recruiting Now)18 (12)
Completed vs Stopped Early4 / 1 (2.8%)
Median Closed Actual Enrollment517 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Mabwell (Shanghai) Bioscience Co
Hospital Research SiteLocationShared Protocols
Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality7
Taizhou Hospital of Zhejiang ProvinceTaizhou, Zhejiang2
Shengjing hospital of China medical universityShenyang, Shenyang2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Mabwell (Shanghai) Bioscience Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07292714A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)Phase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Mabwell (Shanghai) Bioscience Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI